Clinical trials

A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard;dermatologic management on selected dermatologic adverse events among patients with locally;advanced or metastatic EGFR-mutated NSCLC treated first-line with;amivantamab + lazertinib.

A Phase II Study of the BRAF Inhibitor Encorafenib in Combination With the MEK Inhibitor Binimetinib in Patients With BRAFV600E-mutant Metastatic Non-small Cell Lung Cancer

68Ga-FAPI-46 PET/CT for predicting histological response;to neoadjuvant chemo-immunotherapy in triple-negative breast cancer.

First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1047 in Subjects With Malignant Solid Tumors.

A Phase 1, Multicentre, Open-label, Dose-escalation and Cohort Expansion Study of;Niraparib and Dostarlimab in Paediatric Patients with Recurrent or Refractory Solid Tumours

Multicentric randomized phase I/IIa trial of the safety and immunogenicity of a;therapeutic anti-HPV DC targeting vaccine in patients with Human papillomavirus;(HPV)-positive oropharyngeal cancer.

DECLIC Patient Education Program : Assessment Through a Population Health Intervention Research Approach (LE DECLIC EPRI.

A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to;Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With;Chemoradiotherapy (CRT) versus CRT Alone in Participants with Muscle-invasive Bladder;Cancer (MIBC) (KEYNOTE-992)

Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

Single-arm, Multicenter Phase I/Ib Study of Avelumab + Lenvatinib in Children With Primary CNS Tumors.